Sydney, June 13, 2026, 07:02 (AEST)
- Sigma Healthcare closed at A$2.64 on June 12, dropping 1.86% for the day and losing 9.28% in the past week.
- Sigma shares slipped after the company said it’s in early talks tied to the sale of UK pharmacy chain Boots.
- Chemist Warehouse’s sales growth looks strong, but investors are debating how the deal is funded, plus risks around valuation and integration.
Sigma Healthcare Ltd shares slipped this week, with the stock closing at A$2.64, down 1.86% on the day and off 9.28% for the last seven sessions, as investors weighed up if the Chemist Warehouse owner is planning a much bigger play in the UK pharmacy space. The ASX-listed company’s market data is from Intelligent Investor.
The recent drop came after Sigma put out a June 10 ASX statement on talk about Boots, the pharmacy chain out of the UK. Sigma said it had some early talks about the Boots sale process but said there’s no guarantee a deal will take place.
The possible deal is important for Sigma’s stock. Buying Boots could shift Sigma from a mostly Australia-focused pharmacy operator into a bigger international retailer, but it would also mean more debt. Reuters said the Financial Times had named Sigma as a potential buyer for Boots, which could be worth $10 billion. Reuters said it hadn’t been able to confirm the FT story.
Sigma shares fell over 5% on June 10 after news broke of early deal talks, but “Today’s sell-off looks less like a verdict on Boots and more like a reflection of investor caution,” Marc Jocum, senior product and investment strategist at Global X ETFs, told Reuters. The wariness isn’t a surprise. Sigma just wrapped up its merger with Chemist Warehouse, and another big deal would spark fresh questions about debt, the risk of equity dilution, and how management would handle cross-border integration. Reuters
The bull case sticks to the Chemist Warehouse business. Sigma’s May update said Chemist Warehouse branded stores in Australia saw 16.7% sales growth for the financial year so far, with like-for-like up 14.4%. That strips out some new store impact. Sigma added international Chemist Warehouse branded store sales grew 24.7%. The GreenLight Healthcare joint venture gives Sigma a cautious move into the UK, with up to five stores in line for rebranding and development.
Valuation and execution risk weigh on the bear side. Sigma is trading at a market cap near A$30.48 billion, with a price-to-earnings ratio of 43.4. That’s well above the market average and means investors are already pricing in growth. The multiple could make sense if Sigma delivers, but trouble is if the Boots bid costs more than expected, leans on new shares, or pulls focus from integrating Chemist Warehouse.
Sigma is trading just above its 52-week low of A$2.60, despite solid first-half FY26 numbers. Revenue rose 14.9% to A$5.5 billion, normalised EBIT was up 18.7% at A$582.9 million, and normalised NPAT gained 19.2% to A$392.0 million. Today, Sigma looks more risky than cheap on the facts, and the stock is still priced like a growth play.
Sigma investors are now looking for any news on the Boots process—whether Sigma pulls out, goes for binding terms, or releases funding details. After that, eyes turn to Sigma’s FY26 preliminary numbers due August 26 and the annual report out September 16, to see if Chemist Warehouse sales, synergy gains, and international growth can offset the added deal-risk in the share price.
